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Background/Objective: Stroke is a leading global cause of adult disability. As the
population ages as well as suffers co-morbidities, it is expected that the stroke burden
will increase further. There are no established safe and effective restorative treatments
to facilitate a good functional outcome in stroke patients. Cell-based therapies, which
have a wide therapeutic window, might benefit a large percentage of patients, especially
if combined with different restorative strategies. In this study, we tested whether the
therapeutic effect of human adipose tissue-derived mesenchymal stem cells (ADMSCs)
could be further enhanced by rehabilitation in an experimental model of stroke.
Methods: Focal cerebral ischemia was induced in adult male Sprague Dawley rats by
permanently occluding the distal middle cerebral artery (MCAO). After the intravenous
infusion of vehicle (n = 46) or ADMSCs (2 × 106) either at 2 (n = 37) or 7 (n = 7) days
after the operation, half of the animals were housed in an enriched environment mimicking
rehabilitation. Subsequently, their behavioral recovery was assessed by a neurological
score, and performance in the cylinder and sticky label tests during a 42-day behavioral
follow-up. At the end of the follow-up, rats were perfused for histology to assess the
extent of angiogenesis (RECA-1), gliosis (GFAP), and glial scar formation.
Results: No adverse effects were observed during the follow-up. Combined ADMSC
therapy and rehabilitation improved forelimb use in the cylinder test in comparison to
MCAO controls on post-operative days 21 and 42 (P < 0.01). In the sticky label test,
ADMSCs and rehabilitation alone or together, significantly decreased the removal time
as compared to MCAO controls on post-operative days 21 and 42. An early initiation
of combined therapy seemed to be more effective. Infarct size, measured by MRI
on post-operative days 1 and 43, did not differ between the experimental groups.
Stereological counting revealed an ischemia-induced increase both in the density of
blood vessels and the numbers of glial cells in the perilesional cortex, but there were no
differences among MCAO groups. Glial scar volume was also similar in MCAO groups.
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Conclusion: Early delivery of ADMSCs and combined rehabilitation enhanced
behavioral recovery in an experimental stroke model. The mechanisms underlying these
treatment effects remain unknown.
Keywords: stroke, cell therapy, rehabilitation, combination therapy, functional outcome, mechanisms,
translational research
INTRODUCTION
Stroke is one of the leading global causes of death and long-term
disability, with about 5 million survivors becoming permanently
disabled annually (1–3). Despite advances in acute stroke care (4),
the narrow therapeutic time windows for early thrombolysis and
thrombectomy make them available to only about 10% of stroke
patients (5, 6). Safe and effective treatments beyond the acute
phase are urgently needed.
Cell therapy represents a potential breakthrough in the
treatment of stroke. In particular, mesenchymal stem cells
(MSCs) are of major interest due to their advantages over other
cell types, including their abundance and good availability (7),
their relatively low immunogenicity (8) and tumorigenicity (9),
and the lack of ethical concerns (10, 11). The non-invasive
intravenous (IV) route has been most commonly used for
delivery of MSCs in both preclinical and clinical studies (Cui et
al. in press). More importantly, preclinical studies have revealed
evidence for facilitation of behavioral recovery in animal models
of stroke, e.g., improvements in sensorimotor functions (12–14).
Although still unclear, the putative mechanisms include
secretion of neurotrophic factors that promote neuroprotection
against inflammation (15), oxidative stress (14), and apoptosis
(16). Neurorestorative mechanisms such as angiogenesis (17),
neurogenesis (18), synaptogenesis (12), oligodendrogenesis (18),
repair of white matter fiber tracts (19), and remodeling of
neural circuits (20, 21) have also been proposed. In particular,
local angiogenesis is required to provide sufficient oxygen and
nutrients during cerebral reconstruction and remodeling of
damaged tissue, thus this phenomenon plays an important role
in the recovery of neural function after stroke (22). Indeed, it
has been reported that a higher density of blood vessels resulted
in reduced morbidity and prolonged survival of stroke patients
(23, 24).
Recently, adipose tissue-derived mesenchymal stem cells
(ADMSCs) have demonstrated their therapeutic potential in
stroke models by improving the gross neurological condition
(17, 18, 20, 25, 26), sensorimotor function (14, 15, 18, 19, 25,
27), as well as exerting beneficial effects on spatial learning
and memory (7). In fact, the promising preclinical data laid
the foundation for the first safety trial of ADMSCs in stroke
patients (28). Unfortunately, the limited therapeutic efficacy
in early patient studies have indicated that further preclinical
studies are necessary in order to optimize the current cell
treatment protocols.
After the acute phase, rehabilitation therapy is the only
approved treatment for stroke survivors presenting with
neurological deficits (29). In experimental settings, various
rehabilitative approaches such as physical training (30, 31),
skilled training (32–34), and special rehabilitative training
devices (35, 36) have all been employed. In addition, housing
the experimental animals in an enriched environment (EE) has
also been used to provide multiple sensory, motor, social, and
visual stimuli (37). Although very non-specific, housing in EE is
one of the most promising approaches for improving an animal’s
sensorimotor functions after an experimental stroke (38, 39). EE
has also been shown to improve spatial learning and memory in
ischemia-reperfusion models (40).
The combination of different restorative approaches
represents an intriguing approach to maximize treatment effects
(41). Furthermore, cell-based therapies offer the possibility of
combining different neurorestorative strategies to achieve an
additive or even a synergistic therapeutic effect. However, only
a few studies have been published (12, 13, 37, 42–45), and thus,
more research is required in this regard to examine not only
the stand-alone effects of each therapy, but also their potential
combined effect (46, 47). Here, we hypothesized that the
combination of an enriched environment with the IV infusion
of ADMSCs after permanent middle cerebral artery occlusion
(MCAO) would result in an improved behavioral recovery,
perhaps even a maximal therapeutic effect. In order to explore
the therapeutic window, we infused ADMSCs at either 2 or 7
d post-MCAO. Angiogenesis was evaluated as a possible repair
mechanism related to treatment effect. In addition, glial cell
staining was used to assess the extent of gliosis since the presence
of a glial scar is considered to impede neuronal plasticity and
prevent the functional recovery.
MATERIALS AND METHODS
Animals
Ninety-seven adult male Sprague Dawley rats (Envigo, operation
weight 274–340 g) were maintained in a controlled environment
(temperature 20 ± 1◦C; humidity 50–60%; light period 07:00–
19:00) with free access to food and fresh water throughout the
experiment. Animal care procedures were conducted according
to the guidelines set by the European Community Council
Directives 86/609/EEC; and this work was approved by the
Animal Ethics Committee (Hämeenlinna, Finland).
Preparation and Characterization of
Human ADMSCs
The adipose tissue stem cell line RESSTORE01 (Master
Cell Bank/Stock n◦1—Donor RESSSTORE01, Batch n◦:
591133643763) was cultured in the growth medium Alpha MEM
(Gibco, Life technologies) supplemented with 5% human platelet
lysate (Stemulate, Cook Medical, USA) and 1% Penicillin-
Streptomycin (Lonza, Belgium). The medium was changed
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FIGURE 1 | Study design.
twice each week and cells were passaged when they reached
100% confluence. The cells were detached with TrypLE Select
(Life Technologies
TM
, Thermo Fisher Scientific) for 10min
at 37◦C and then centrifuged at 1,000 rpm for 5min. The
RESSTORE01 cell phenotype was analyzed with flow cytometry
(FACSAria Fusion Cell Sorter, BD Biosciences) at passage PX
+1. Monoclonal antibodies against CD19-phycoerythrincyanine
(PE-Cy7), CD45RO-allophycocyanin (APC), CD73-PE, CD90-
APC (BD Biosciences), CD11a-APC, CD105-PE (R&D Systems
Inc., Minneapolis, MN, USA), CD34-APC and HLA-DR-PE
(Immunotools GmbH, Friesoythe, Germany) were used. The
cells expressed (>95%) surface markers CD73, CD90, and
CD105 and lacked the expression (<2%) of CD11a, CD19,
CD34, CD45, and HLA-DR. Cells at passages PX+2/3 were used
for the study.
Permanent Middle Cerebral
Artery Occlusion
Anesthesia was induced with 5% isoflurane in 30 O2/70% N2O
and maintained during the operation with 2% isoflurane. The
temperature of the rats was kept constant (37 ± 0.5◦C) with
a heating blanket and rectal probe (Harvard Homeothermic
Blanket Control Unit; PanLab, Barcelona, Spain). In the
occlusion of the rightmiddle cerebral artery (MCA), the temporal
muscle was removed to expose the temporal bone and a 2–3mm
diameter hole was drilled on top of the artery while cooling the
bone with ice-cold 0.9% NaCl. The dura was carefully removed
after which the artery was occluded with an electrocoagulator
(Aesculap, Center Valley, PA, USA). Immediately after the MCA
occlusion, both common carotid arteries (CCA) were occluded
with micro-aneurysm clips for 60min. After 1 h, the clamps
were slowly released, the temporal muscle was replaced, and
the incision/wound was sutured. The sham-operated rats went
through all of the same procedures except for the occlusion
of MCA and CCAs. To assist rehydration, 5ml of 0.9%
NaCl was given intraperitoneally. Buprenorfine (Temgesic, 0.03
mg/kg) was injected subcutaneously immediately after surgery as
an analgesic.
Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) was performed 24 h after the
operation and on post-operative day 43 (Figure 1) using a Bruker
9.4 T horizontal scanner. The rats were anesthetized with 5%
isoflurane in 30 O2/70% N2. After induction, the anesthesia was
maintained throughout the imaging with 1.5% isoflurane inhaled
through a nose mask. In the determination of the infarct volume,
T2 weighted multi-slice images were acquired using a RARE
sequence with the following parameters: time-to-repetition TR=
2.5 s, effective time-to-echo effTE= 40ms, RARE factor 8, matrix
size of 256 × 256, field-of-view of 30 × 30mm, 15 slices with a
slice thickness of 1mm. T∗2 weighted images were obtained using
a standard gradient echo imaging sequence from the same slices
with identical resolution and TR= 700ms, TE= 15ms, flip angle
∼50◦. The cortical infarct volume was measured using in-house
written Matlab software. Animals with infarct size <20 mm3 (n
= 5) or>150 mm3 (n= 2) were excluded from the data analysis.
These exclusion criteria had been decided before the experiment.
Cell Treatment and Housing in
Enriched Environment
The animals were sequentially assigned to experimental groups
based on initial screening on MRI to ensure that the infarct
size did not differ between experimental groups before treatment
(Table 1). Two days after the occlusion procedure, isoflurane
anesthetized rats were slowly infused with 2 million cells/1ml
0.9% NaCl into the tail vein. Vehicle groups were treated with
1ml 0.9% NaCl. Additional animals were treated 7 days after
MCAO (Figure 1). Body weight was recorded during the follow-
up as part of the safety assessment. After the infusion of the
cells, half of the rats were moved to an enriched environment
that consisted of two large metal cages (61 × 46 × 46 cm)
that were connected by a tunnel. The cages contained ladders,
tunnels, shelves and a running wheel to provide sensorimotor
stimuli. Novel objects (e.g., toys, wooden balls) were changed
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TABLE 1 | Experimental groups.
Groups Treatment Housing Timing
Vehicle Cell Standard EE 2 d 7 d
SHAM SHAM+V+S (n = 8) x x x
SHAM+C+S (n = 8) x x x
SHAM+V+EE (n = 8) x x x
SHAM+C+EE (n = 8) x x x
MCAO MCAO+V+S (n = 12) x x x
MCAO+C+S (n = 10) x x x
MCAO+V+EE (n = 10) x x x
MCAO+C+EE (n = 11) x x x
MCAO+V7+EE (n = 8) x x x
MCAO+C7+EE (n = 7) x x x
SHAM, sham-operated; MCAO, middle cerebral artery occlusion; V, 2 d vehicle; C, 2
d cell infusion; V7, 7 day vehicle; C7, 7 day cell infusion; S, standard housing; EE,
enriched environment.
every second day. Altogether, 8–9 animals were housed per cage.
The animals in the non-rehabilitation group were housed in
groups of three rats in standard cages (53× 32.5× 20 cm).
Behavioral Testing
All behavioral tests were carried out in a blinded manner
1 day before the occlusion procedure and on post-operative
days (between 9 and 12 a.m.) as shown in Figure 1. Behavioral
impairment was assessed using the Rogers’, cylinder and
sticky label tests. Two animals were excluded from the sticky
label test analysis due to problems with their teeth and
behavioral peculiarities.
Rogers’ Test
The Rogers’ functional evaluation scale was used to assess
the gross behavioral impairment, including reflexes, sensory
responses, and simple motor functions (17). It consists of a 7-
point behavioral rating scale: score 0—no functional deficit; score
1—failure to extend left forepaw fully; score 2—decreased grip of
the left forelimb while tail gently pulled; score 3—spontaneous
movement in all directions, contralateral circling only if pulled by
the tail; score 4—circling or walking to the left; score 5—walking
only when stimulated; score 6—unresponsive to stimulation with
a depressed level of consciousness; and score 7—dead.
Cylinder Test
The cylinder test was used to measure spontaneous forelimb
use and imbalance between the non-impaired and impaired
forelimbs (48). In this test, the rat was placed in a transparent
plastic cylinder (Ø 20 cm) and video-recorded (5min) through
a mirror placed under the cylinder. The videotaped exploratory
activity in the cylinder was analyzed for 1 to 3min using
a program with slow motion capabilities. The number of
contacts on cylinder by either the impaired or the non-impaired
forelimb or both forelimbs was counted (minimum 30 contacts).
The imbalance in forelimb use was calculated as: [(use of
impaired forelimb + 0.5 × use of both forelimbs) ÷ (total
contacts)]× 100%.
Sticky Label Test
The sticky label test was used to evaluate sensory function and
motor learning, and was performed as previously described
(48). Before testing, the animals were familiarized with handling
and the testing cage. In the test, a white colored circular label
(Ø 9mm, Tough-Spots, Diversified Biotech) was placed on the
distal-radial region of both wrists and rat was moved to a test
cage. The time for the first contact to the label and time to remove
the label were measured. A maximum time of 120 s was set if the
rat was not able to contact or remove the label.
Histology
After the behavioral assessment, rats were perfused on post-
operative day 44 (Figure 1) with 0.9% NaCl followed by 4%
paraformaldehyde in 0.1M phosphate buffer, pH 7.4. The
brains were carefully removed from the skull, post-fixed,
and cryoprotected. Brain sections (35 um) were cut using a
sliding microtome and stored in antifreeze solutions at −20◦C.
Systematically sampled sections with a random start covering
the entire infarct were selected for staining and analysis. One
series of sections was stained with the angiogenesis marker, anti-
RECA-1 antibody, and another series with the gliosis marker,
anti-GFAP antibody.
RECA-1 Immunohistochemistry
The sampled sections were stained with anti-RECA-1 antibody to
visualize blood vessels. Briefly, free-floating sections were washed
in 0.1M phosphate buffer (PB) (3 × 15min) and kept overnight
in a cold room. They were then rinsed with 0.5M Tris buffered
saline + Triton (TBS-T) at pH 7.6 (3 × 5min) before treatment
with the primary antibody mouse anti-rat RECA-1 (AbD Serotec,
Bio-Rad) at 1:2000 in TBS-T at pH 7.6 for 18 h on a shaker table
in the dark at room temperature. Afterwards, the sections were
rinsed in TBS-T at pH 7.6 (3 × 5min) and then treated with
secondary antibody biotinylated anti-mouse IgG (Vector) made
in goat at 1:500 in TBS-T at pH 7.6 for 2 h on a shaker table, room
temperature. Subsequently, the sections were rinsed in TBS-T at
pH 7.6 (3 × 5min), followed by treatment with Streptavidin-
horseradish peroxidase conjugate (GE Healthcare UK Limited)
at 1:1000 in TBS-T at pH 7.6 for 2 h on a shaker table at room
temperature. The sections were again rinsed in TBS-T at pH 7.6
(3 × 5min) and then carefully developed with filtered nickel-
intensified DAB (Sigma) for∼3min. Excess DABwas rinsed with
PB (3 × 4min) before the sections were mounted and kept at
37◦C overnight. The mounted sections were then washed in PB
for 5min before they were counterstained with thionin to reveal
the neuroanatomy and delineate the perilesional area. They were
then cleared in xylene (2 × 5min) and coverslips were mounted
using Depex.
GFAP Immunohistochemistry
Other sets of sampled sections were stained with anti-GFAP
antibody to visualize astrocytes. Briefly, free-floating sections
were washed in PB (3 × 15min) and kept overnight in a cold
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room. They were then washed in TBS-T at pH 8.6 (2 × 5min)
before incubating in primary antibodymouse anti-GFAP (Sigma)
at 1:1000 in TBS-T at pH 8.6 for 18 h on a shaker table in the
dark at room temperature. The sections were again rinsed in
TBS-T at pH 8.6 (3 × 5min) and then treated with secondary
antibody goat anti-mouse IgG-HRP conjugated (Invitrogen) at
1:500 in TBS-T at pH 8.6 for 2 h on a shaker table at room
temperature. Afterwards, the sections were rinsed in TBS-T at pH
8.6 (3× 5min) and then carefully developed with filtered nickel-
intensified DAB for ∼3min. Excess DAB was rinsed with PBS
(3 × 4min) before the sections were mounted and kept at 37◦C
overnight. Finally, the mounted sections were cleared in xylene
(2× 5min) and coverslips were mounted using Depex.
Histological Analysis
The analysis was done with the aid of Stereo Investigator
software (MicroBrightField, Inc., VT, USA) attached to an
ECLIPSE E600 microscope (Nikon, Japan) via a 3-Chip CCD
color video camera (QImaging, Canada). A motorized stage with
a microcator (Heidenhain EXE 610C) attachment (providing a
0.1µm resolution in the Z axis) was mounted on the microscope.
In the assessment of angiogenesis, the perilesional tissue
200µm from the ischemic border around the lesion was first
outlined under 4x magnification (N.A. 0.06) and thereafter blood
vessels were counted under 20x magnification (N.A. 0.75). To
determine the vessel density in sections stained with RECA-1,
we used the virtual sphere method (49). A three-dimensional
sampling hemisphere (“space ball”) with a radius of 20µm was
placed within a sampling box with known dimensions (x =
200µm, y = 200µm, and z = 20µm) and focused through
the section thickness. The x-y steps giving the distance between
sampling areas was 400µm (x-axis) by 400µm (y-axis), aimed at
generating counts of about 300 vessel intersections per animal. In
order to calculate the total length of blood vessels, the following
equation was used: Ltotal = 6Q × 2 × 1/ssf × 1/asf × 1/tsf ×
[v/a], where Q is the number of intersections between vessels
and the probe, ssf (section sampling fraction) is 1/15, asf (area
sampling fraction) is 0.03, tsf (tissue sampling fraction) is 1,
and v/a is 19.2µm [defined as the ratio of the volume (v)
of the counting frame (sampling box) to the surface area (a)
of the hemisphere probe (space ball)]. The vessel density was
counted as the ratio of measured length and the total volume of
perilesional area.
The optical fractionator technique was used to measure the
glial scar and to assess the total number of GFAP labeled cells in
the perilesional area (50). The glial scar was defined as glial cell
aggregation. The perilesional zone was defined as a 200µm wide
cortical zone directly surrounding the scar. The cut thickness of
the tissue was 35µm and the average mounted thickness was
20µm. The size of the counting frame was 100 × 100µm, with
the height of the dissector cube of 20µm and a grid of 200 ×
200µm. The perilesional area and the scar area were traced using
a 2x objective (N.A. 0.10) and the number of GFAP positive
cells was counted using a 20x objective (N.A. 0.75). A GFAP
positive cell was counted when the cell soma did not intersect
with the uppermost focal plane (exclusion plane) and the lateral
exclusion boundaries of the counting frame. The perilesional
area reference volume was determined by adding the traced
perilesional area for each section multiplied by the distance
between sections sampled. For the total number of GFAP positive
cells, the following equation was used: Ntotal = 6Q × 2 × 1/ssf
× 1/asf × 1/tsf. The number of GFAP labeled cells was then
related to a total perilesional volume. The enclosed volume of
the scar was acquired from the contour summary provided by
Neurolucida software (MicroBrightField, Inc.).
Statistical Analysis
Statistical analyses were performed using SPSS software for
Windows (version 25). One-way analysis of variance (ANOVA),
followed by the LSD post-hoc test if necessary, was used to
analyze the statistical differences between groups in infarct
volume, RECA-1, and GFAP staining. The Kruskal-Wallis H
test, followed by the Mann-Whitney U-test if necessary, was
used to compare the neurological scores. Repeated measures
ANOVA, followed by the LSD post-hoc test if necessary, was
used to analyze behavioral data from the cylinder and sticky label
tests. Spearman and Pearson correlations were used to examine
the relationship between behavioral impairment and infarct size,
angiogenesis, and gliosis. Data are expressed as mean± standard
deviation (SD).
RESULTS
Intravenous ADMSC Infusion Was Not
Associated With Mortality or
Adverse Effects
To assess the safety of ADMSC treatment, we carefully monitored
the rats during the follow-up. There was no mortality after
infusion of either cells or vehicle. Weight gain was similar in all
experimental groups (see Supplemental Table 1). Safety was also
evaluated using the Rogers’ scale on post-operative days 1, 2, 3, 5,
7, 21, and 42 (see Supplemental Table 2). There was a statistically
significant difference (P < 0.001) in neurological scores at all
time points after the occlusion procedure, demonstrated by the
better performance in the sham-operated groups compared to the
MCAO groups. No statistically significant differences were found
between vehicle- and cell-treated groups at all post-operative
time points (data not shown).
Infarct Size Was Not Affected by ADMSCs
There were no differences in the cortical infarct size between the
experimental groups at 24 h after operation (Figure 2A). In order
to determine whether the therapeutic effect would be related to
delayed neuroprotection, the infarct size was measured also at
the end of the follow-up (Figure 2B). A variable maturation of
infarct was observed, in many cases leading to a liquid-filled
cyst. However, the infarct size did not differ between control and
cell-treated groups on post-operative day 43.
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FIGURE 2 | Infarct size and location. Infarct size 24 h (A) after MCAO in rats and at the end of the follow-up on day 43 (B). MRI images show the location of a typical
infarct in the sensorimotor cortex at these time points.
FIGURE 3 | Cylinder test. Impaired forelimb use during the vertical exploration in the cylinder test was improved by ADMSC treatment and housing in an enriched
environment in MCAO rats. Statistical significance: **P < 0.01; ***P < 0.001 (compared to SHAM+V+S), ##P < 0.01 (compared to MCAO+V+S). SHAM,
sham-operated; MCAO, middle cerebral artery occlusion; V, 2 d vehicle; C, 2 d cell infusion; S, standard housing; EE, enriched environment.
ADMSC Infusion and EE Improved
Spontaneous Forelimb use in MCAO Rats
Treatment effects were assessed by the performance of the
animals in the cylinder and sticky label tests on post-operative
days 7, 21, and 42.
Cylinder Test
The imbalance in the spontaneous forelimb use during vertical
exploration was assessed in the cylinder test (Figure 3). There
was a significant overall group effect (P < 0.001) and time ×
group interaction (P < 0.001). In the more detailed analysis,
significant time × group interactions were found between
standard-housed vs. EE-housed (P< 0.01) as well as with vehicle-
treated vs. ADMSCs-treated (P < 0.05) animals, showing that
recovery of the impaired forelimb was different between the
groups. All MCAO groups were different from SHAM+V+S on
post-operative day 7. TheMCAO+V+S group displayed a slower
recovery on post-operative day 21. MCAO+V+S control rats
were different from the MCAO+C+EE group on post-operative
days 21 and 42 (P < 0.01). The amount of spontaneous forelimb
use at the end of the follow-up correlated with infarct size on
post-operative day 1 (r =−0.440, P < 0.01), blood vessel density
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TABLE 2 | Correlations of behavioral outcome at the end of the follow-up with
infarct size (24 h), angiogenesis and gliosis.
Rogers’ test Cylinder test Sticky label test
Time to first
contact
Time to
remove
Infarct size
(24 h)
r = 0.311;
P < 0.05
r = −0.440;
P < 0.01
NS NS
Blood vessel
density
NS r = −0.278;
P < 0.01
NS NS
Number of
glial cells
r = 0.530;
P < 0.001
r = −0.550;
P < 0.001
NS NS
Glial scar
volume
NS NS NS NS
NS, not significant.
(r = −0.278; P < 0.01), and number of glial cells (r = −0.550; P
< 0.001) (Table 2).
Sticky Label Test
The sticky label test was performed to evaluate sensorimotor
function and motor learning (Figure 4). With respect to the
impaired forelimb, there were no significant overall group effect
(P = 0.055) or any time × group interaction (P = 0.138) on
the time for the first contact with the label (Figure 4A). With
respect to the time to remove the label, there was a significant
overall group effect (P < 0.01) and a time × group interaction
(P < 0.01). MCAO+V+S rats used more time to remove the
label as compared to SHAM+V+S (P < 0.01) or animals in
the other MCAO groups (P < 0.01) on post-operative day 21.
At the end of the behavioral follow-up, MCAO+V+S controls
were different from SHAM+V+S (P< 0.01), MCAO+C+S (P<
0.05), and MCAO+C+EE (P < 0.01) groups (Figure 4B). With
respect to the non-impaired forelimb, there were no significant
overall group effects and time× group interactions for the time to
the first contact with the label or for the time required to remove
the label (data not shown).
Cell Infusion on Post-operative Day 7 Was
Not Effective as When Cells Infused on
Day 2
The optimal therapeutic time window for combined therapy
was assessed by comparing treatment starting on days 2 and
7. There were no significant overall group effects or time ×
group interactions in the cylinder test (Figure 5A) or sticky
label test (Figures 5B,C), when cell infusion on days 2 and 7
were compared. However, a trend toward a better recovery was
observed when cells were delivered earlier.
The Extent of Angiogenesis or Gliosis Was
Not Related to the Behavioral Recovery
Perilesional cortex undergoes a major reorganization after
cerebral ischemia, a phenomenon thought to be related to the
behavioral recovery. Here, we measured the formation of new
blood vessels as a mechanism behind the behavioral recovery and
we also assessed the extent of glial scar formation that might
hinder the recovery process.
Angiogenesis
The overall distribution of RECA-1 stained blood vessels in the
cortex is shown for a sham-operated rat (Figure 6B) and for a
MCAO rat (Figure 6C). Figure 6A shows how the perilesional
cortex was defined. There was a significant difference (P < 0.01)
in the blood vessel density in the cortex due to the difference
between sham-operated andMCAO animals. However, there was
no significant difference between theMCAO groups (Figure 6D).
Glial Cells and Glial Scar
Figure 7A shows GFAP staining for resting glial cells in a
sham-operated rat with Figure 7B revealing the change in
the phenotype into hypertrophic reactive astrocytes and scar-
forming astrocytes in the perilesional cortex after ischemia. There
was a significant overall effect in the number of glial cells in
perilesional cortex (P < 0.001) (Figure 7C); this was due to an
increase in the number of glial cells in MCAO animals. However,
there was no significant difference between the MCAO groups
nor was there any significant difference between MCAO groups
in the glial scar volume (Figure 7D).
DISCUSSION
In this experimental model of stroke, we investigated whether
the therapeutic effect of human ADMSCs could be further
enhanced by rehabilitation. We found that cell therapy or
rehabilitation alone improved the functional recovery of the
impaired forelimb, when treatment was started 2 days after the
induction of ischemia. Combined therapy further improved the
behavioral outcome. Delayed neuroprotection, angiogenesis or
altered gliosis did not explain the behavioral improvement.
Methodological Issues
ADMSCs are easy to obtain in large quantities (7), have no ethical
concerns (10, 11), and have an excellent safety profile (9, 17).
The same cell product is being used in the ongoing RESSTORE
clinical trial (NCT03570450). The MCAO stroke model was
selected according to recent SRRR guidelines (51). It produces a
consistent infarct in the sensorimotor cortex causing a moderate
behavioral impairment and partial spontaneous recovery in the
long-term follow-up. The somewhat large variability in infarct
size, which was also reflected in behavioral scores, and thus
complicating the statistical analysis, is possibly due to the rat
strain. The selected outcomemeasures are sensitive at identifying
treatment effects and are not affected by repeated testing, but
combined treatment effects can be missed by the presence of
spontaneous recovery and of a ceiling effect.
Our study also has some methodological limitations. Young
male rats were used, although the main unmodifiable risk factor
for stroke is aging, which may impair brain repair including
angiogenesis (52), and also decrease the therapeutic effect of cells
(53). Thus, aging as well as co-morbidities such as hypertension
and diabetes (54) should be addressed despite the fact that they
further complicate the study design. As far as we are aware, this is
the first time that stereology has been used to evaluate the extent
of brain repair in a stroke model. However, since the RECA-
1 antibody stains all blood vessels, perhaps CD31 (PECAM-1)
staining would have revealed post-stroke angiogenesis (52). The
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FIGURE 4 | Sticky label test. Time needed before the first contact was not different between the experimental groups (A). The time to removal of sticky label from
impaired forelimb was increased in MCAO rats, an effect partially reversed by ADMSCs an EE (B). Statistical significance: **P < 0.01 (compared to SHAM+V+S); #P
< 0.05, ##P < 0.01 (compared to MCAO+V+S). SHAM, sham-operated; MCAO, middle cerebral artery occlusion; V, 2 d vehicle; C, 2 d cell infusion; S, standard
housing; EE, enriched environment.
FIGURE 5 | Timing of cell delivery. Early ADMSC delivery (48 h) in MCAO rats seemed to improve forelimb use when compared to delayed delivery (7 d) as assessed
in the cylinder test (A) and sticky label test: time to touch (B), time to remove (C). MCAO, middle cerebral artery occlusion; V, 2 d vehicle; C, 2 d cell infusion; V7, 7
day vehicle; C7, 7 day cell infusion; EE, enriched environment.
only reliable way to differentiate between new and old blood
vessels would be to conduct BrdU/RECA-1 double staining.
Intravenous ADMSC Delivery Is Safe
The safety of new therapies is of the utmost importance
(55); however, it is often overlooked unless demanded by
the regulatory authorities. In the present study, we did not
observe mortality due to pulmonary embolism or any other
reasons; weight gain was similar in all groups; the gross
neurological evaluation revealed no abnormalities in sham-
operated or ischemic rats after cell treatment; and MRI images
were clean with no sign of bleeding. These all support the
concept that the used cell product, dose and delivery route
were safe in our rat stroke model. However, regulatory safety
studies will need to be carried out before embarking on
patient trials.
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FIGURE 6 | Quantification of perilesional angiogenesis. Definition of perilesional cortex 200µm from the border of ischemic core (A). Representative RECA-1 staining
with thionin counterstaining in sham-operated (B), and MCAO (C) rats. Stereological analysis showed ischemia-induced increase in blood vessel density in perilesional
cortex (D). Scale 1mm (A), 50µm (B,C). Statistical significance: *P < 0.05 (compared to SHAM+V+S). SHAM, sham-operated; MCAO, middle cerebral artery
occlusion; V, 2 d vehicle; C, 2 d cell infusion; S, standard housing; EE, enriched environment.
FIGURE 7 | Quantification of perilesional gliosis. Representative staining of GFAP-stained sections from a sham-operated rat (A) and an MCAO rat (B). Stereological
analysis revealed an ischemia-induced increase in the number of glial cells in the perilesional cortex (C). Glial scar volume did not differ between the MCAO groups
(D). Scale 50µm. Statistical significance: ***P < 0.001 (compared to SHAM+V+S). SHAM, sham-operated; MCAO, middle cerebral artery occlusion; V, 2 d vehicle;
C, 2 d cell infusion; S, standard housing; EE, enriched environment.
Early ADMSC Transplantation Improves
Sensorimotor Recovery
Promising behavioral improvements have been reported in
experimental stroke models following IV infusion of MSCs (12,
13), including ADMSCs (15, 19, 20, 27). Consistent with these
studies, we observed that the spontaneous use of the impaired
forelimb in the cylinder test had been improved by the infusion
of the ADMSCs. In addition, 2 d post-stroke delivery of ADMSCs
to the MCAO rats resulted in a significant decrease in the time
needed to contact and particularly, to remove sticky labels from
the impaired forelimb.
The critical time window during which the brain is most
responsive to cell therapy is not known. In most of the
experimental studies, cells have been infused within 24 h after
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brain ischemia (Cui et al. in press), although later time points
have also been evaluated (7, 56). Here we found a trend toward
a better recovery when the cells were delivered earlier. While
early delivery might provide neuroprotection, that hypothesis
was however not supported by the present data. Furthermore, the
recent phase II MASTERS study in stroke patients supports the
efficacy of early delivery (57). In addition, there is accumulating
evidence suggesting that intravenously delivered cells modulate
peripheral immune systems within another specific time window
i.e., 24–48 h post-stroke, improving functional recovery (58).
This is the target in the ongoing phase III MASTERS-2 study in
stroke patients (NCT03545607).
The relatively modest behavioral improvement in our study
could be due to the loss of cells after xenogenic transplantation.
The differences in the clearances of human and rat bone marrow-
derived MSCs after systemic infusion support this proposal (59).
However, both allogenic and xenogenic delivery of ADMSCs
have been effective in experimental stroke (7, 15, 17, 26, 27, 56).
Cell entrapment in lungs might also affect the efficacy of the
treatment, although it is still not clear whether the cells have to
enter the brain parenchyma to play a role in behavioral recovery
(60). Lastly, when robust study quality criteria are applied (e.g.,
randomization, blind assessment), the preclinical results are not
so convincing and are more in line with the relatively modest
evidence of efficacy emerging from small patient studies.
EE Results in a Modest Improvement in
Sensorimotor Functions
Experimental stroke rehabilitation is an emerging research area.
The available data does not support the belief that one particular
approach is superior to the others (61). In our study, we examined
the benefits of an enriched environment, which provides spatial,
sensory, motor, and social stimuli for rodents. This is known to
be one of the most powerful forms of experimental rehabilitation
(39), improving not only gross neurological and sensorimotor
functions (38, 62–64), but also spatial learning and memory after
cerebral ischemia (40, 65). In our study, housing in the enriched
environment, when started on post-operative day 2, improved
spontaneous forelimb use in the cylinder test and reduced the
removal time in the sticky label test.
A major problem with enriched environment is that the
overall stimulation varies and is dependent on the activity of
the animal. Thus, it remains to be determined whether intensive
or forced physical training or a more controllable and task-
specific exercise such as skilled forelimb reaching to supplement
the enriched environment would have been more effective (66).
One way to increase treatment contrast would be to house
control rats in single cages. In the present study, three rats
were housed in the same cage as demanded by the animal
ethics committee.
Combined Therapy Seems to Further
Improve Sensorimotor Functions
The wide therapeutic time windows for both cell therapy and
rehabilitation allow their combination. Although the prospect
of combining different neurorestorative approaches to maximize
the therapeutic effect is theoretically very interesting (41), to date,
very few studies have utilized this research strategy (12, 13, 37,
42–45). In our study, we found that combining ADMSC at 2 d cell
delivery with EE in MCAO animals increased the spontaneous
use of the impaired forelimb during vertical exploration. The
impaired forelimb had almost completely recovered by the end
of the follow-up. In addition, the time needed to remove sticky
labels from their impaired forelimb was significantly reduced.
However, the spontaneous recovery, complex study design and
challenging statistics did not make it possible to discriminate the
add-on therapeutic effect. To achieve this, multicenter preclinical
trials with greater statistical power will be needed (67).
Cell treatment and housing in EE was started at the same
time but it is not known whether this is the most optimal
approach. Interestingly, there is recent evidence that a timed
sequence of treatments could maximize the therapeutic effects
in experimental stroke animals (68). In the case of cell therapy,
stabilization with nonselective stimulation such as an enriched
environment might be preferable after the initiation of the brain
plasticity by the infused cells.
Neuroprotection may also be a prerequisite for delayed
cortical plasticity and functional recovery. In the elegant work
of Fernández-García et al. (69), transplantation of mesenchymal
stem cells alone into strokemice was not effective as these animals
showed permanent sensorimotor deficits in the grid walking test.
However, when cells where encapsulated in silk fibroin hydrogel,
significant cortical neuroprotection was observed, leading to
delayed remapping of forelimb representations and a behavioral
recovery similar to that associated with rehabilitation.
Perilesional Angiogenesis or Gliosis Does
not Explain the Behavioral Recovery
The brain repair mechanisms underlying spontaneous or
therapy-induced recovery after stroke are still poorly understood
(70). However, there is emerging evidence that in particular
the perilesional tissue undergoes a major remodeling to foster
restitution of function in damaged areas (71).
Angiogenesis, i.e., the formation of new capillaries, is
restricted to the border of the infarct and it is claimed to aid
in cleansing the necrotic brain tissue (72) as well as providing
a site for neuroblast migration (73). MSCs further promote
angiogenesis and this has been associated with improved
behavioral outcome (74). Consistent with previous studies, we
could confirm the ischemia-induced increase of angiogenesis in
MCAO rats but were not able to demonstrate any treatment
effect. Previous studies that reported increased angiogenesis and
improved behavioral performance employed a follow-up period
between 14 and 21 days (14, 17, 18). In our study, it may be
that ADMSCs only transiently promoted angiogenesis during the
early behavioral recovery and this was missed when evaluated
after a relatively long follow-up. A temporal monitoring of
the extent of angiogenesis at different time points until the
end of the follow-up could have been helpful. Furthermore, as
previously stated, perhaps a BrdU/RECA-1 double labeling to
differentiate old and new blood vessels would have better revealed
a treatment effect.
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The glial cell response to brain ischemia and glial scar
formation are also involved in perilesional remodeling and
functional recovery (75). The presence of a glial scar has
been claimed to impair repair processes (76). MSCs including
ADMSCs decrease perilesional GFAP labeling, a marker for
glial cells (17). We detected an increase in the number of
glial cells in the perilesional cortex, but no differences between
the MCAO groups. In addition, there were no differences in
glial scar volume between the MCAO groups. Nonetheless,
possible temporal changes in glial cell phenotype attributable to
either the ADMSCs and/or the enriched environment cannot
be excluded.
Clinical Implications
Most stroke patients receive some form of rehabilitation.
Nonetheless, there is still no agreement about which modalities
should be used nor how and when they should be applied.
Rehabilitation is a major confounding factor in clinical
stem cell trials and it should be taken into account or
carefully controlled. Our data strongly support this view.
Indeed, the importance of rehabilitation has already been
included into the STEPS 3 recommendations (47). However,
complex study designs are needed to discriminate add-on
and stand-alone therapeutic effects, although these might
not be feasible in experimental studies and even less so in
clinical trials.
CONCLUSIONS
The combination of multiple regenerative treatments to improve
stroke recovery is an attractive strategy. Here we demonstrated
that intravenous delivery of ADMSCs and housing in an
enriched environment is a safe treatment and improved the
behavioral recovery of MCAO rats with a further improvement
associated with the combined treatment. The treatment effect
was not associated with neuroprotection or altered perilesional
angiogenesis or the extent of glial scar formation, but this
does not exclude the possibility that there was altered neuronal
excitability or axonal sprouting. Further studies with greater
statistical power to cope with complex study designs will be
needed to determine the optimal protocol and to reveal the true
value of combination therapies in stroke.
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